RAPP

Rapport Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000

$25.05Close $1.2BMarket cap $22.50 – $52.5052-week range Nov 5, 2026Next report

Highlights

Cautions

Not in an uptrend 1 of 8 trend conditions
Lagging the market RS 12 · weaker than 88% of stocks over 12 months
Far from its high 52% below its 52-week high
Results soon Nov 5, 2026, in 4 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 5, 2026

Off 12-month high 52%

1wk 3.4% price change

1mo 25.4% price change

12-month return 7% market up 11% · its own down 19%

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B 2.5× price / book

Earnings yield 10.9% EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 28% return on equity

Free cash margin — -$88.1M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 10.7% $2.68 a day · 2×ATR $19.69

RS 12 / 99 vs the universe

Trend 1 / 8 trend template

Relative volume 1.2× vs 50-day average

Up/down volume 1.01 50 sessions

Implied move — no option chain · report Nov 5, 2026

Contractions 2 49% → 30%

Pivot $31.31 20.0% below

Volume dry-up 3.1× 10 vs 50 sessions

Trend template · 1 of 8

150-day average above the 200-day: passes

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 30.6% over the year, from 37m to 48m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Oct 30, 2026

Last shock Oct 28, 2026-18% in one session8.0× volumeon results+11% since

Financials

3 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$111.5M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$88.1M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 47.77m +1045.4% since FY2023

	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Operating income	-$36.2M	-$83.1M	-$125.1M
Net income	-$34.8M	-$78.3M	-$111.5M
Earnings per share	-$23.10	-$3.78	-$2.86
Free cash flow	-$28.8M	-$67.2M	-$88.1M
Cash	$70.2M	$56.8M	$52.6M
Shareholders' equity	-$25.6M	$305.4M	$484.7M
Shares outstanding	4.17m	36.58m	47.77m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 5, 2026	Quarterly ↗	Jun 30, 2026	36d
May 7, 2026	Quarterly ↗	Mar 31, 2026	37d
Mar 10, 2026	Annual ↗	Dec 31, 2025	69d
Nov 6, 2025	Quarterly ↗	Sep 30, 2025	37d
Aug 7, 2025	Quarterly ↗	Jun 30, 2025	38d
May 8, 2025	Quarterly ↗	Mar 31, 2025	38d
Mar 11, 2025	Annual ↗	Dec 31, 2024	70d
Nov 7, 2024	Quarterly ↗	Sep 30, 2024	38d
Aug 8, 2024	Quarterly ↗	Jun 30, 2024	39d

Current reports

Filed	Disclosed
Oct 30, 2026	Material agreement · Results · New obligation · Unregistered share sale ↗
Oct 20, 2026	Regulation FD · Other events ↗
Aug 5, 2026	Results ↗
Jun 10, 2026	Shareholder vote ↗
May 7, 2026	Results ↗
Apr 21, 2026	Regulation FD · Other events ↗
Mar 10, 2026	Results ↗
Jan 7, 2026	Other events ↗
Jan 7, 2026	Regulation FD · Other events ↗
Nov 6, 2025	Results ↗
Sep 10, 2025	Material agreement ↗
Sep 8, 2025	Other events ↗